CN103142982A

CN103142982A - Medicine for treating acute upper respiratory infection

Info

Publication number: CN103142982A
Application number: CN 201310111251
Authority: CN
Inventors: 王健
Original assignee: Individual
Current assignee: Individual
Priority date: 2013-03-22
Filing date: 2013-03-22
Publication date: 2013-06-12

Abstract

The invention relates to a medicine for treating acute upper respiratory infection. The medicine for treating acute upper respiratory infection comprises the following components in parts by weight: 5-10 parts of radix scrophulariae, 10-20 parts of dried ginger, 20-30 parts of dogwood, 10-20 parts of platycodon grandiflorum, 15-25 parts of angelica dahurica, 5-15 parts of inula flower, 10-30 parts of cowherb seed, 1-15 parts of herba aristolochiae, 10-20 parts of radix sileris, 15-30 parts of capillary artemisia, 20-30 parts of radix bupleuri, 1-20 parts of morinda officinalis, 1-20 parts of celandine, 10-25 parts of rhizoma imperatae, 10-30 parts of cocklebur fruit, 1-20 parts of emblic leafflower fruit, 15-20 parts of kamuning, 10-20 parts of radix phytolaccae, 15-20 parts of butterflybush flower, 15-30 parts of glabrous sarcandra herb, 10-20 parts of radix ranunculi ternati, 10-25 parts of folium sennae, 5-15 parts of aleppo avens, 1-20 parts of uniflower swisscentaury root, 15-25 parts of folium rhododendri daurici, 15-25 parts of rhizoma cyperi, 10-20 parts of calyx seu fructus physalis, 15-25 parts of white mulberry root-bark, 20-30 pars of lindley eupatorium, 1-20 parts of gorgon euryale seed and 10-25 parts of chinese azalea flower. All the components of the medicine for treating acute upper respiratory infection are natural materials, so that the medicine for treating the acute upper respiratory infection has good safety and clear curative effect and is suitable for large-scale application in clinic.

Description

A kind of medicament for the treatment of acute upper respiratory tract infection

Technical field

The present invention relates to field of medicaments, relate in particular to a kind of medicament for the treatment of acute upper respiratory tract infection.

Background technology

Acute upper respiratory tract infection is the general title of nasal cavity, pharynx or acute throat inflammation.The commonly encountered diseases substance is virus, and minority is antibacterial.Its morbidity is without age, sex, occupation and regional difference.The general state of an illness is lighter, and the course of disease is shorter, the prognosis bona.But because sickness rate is high, have certain infectiousness, not only affect input of labor, sometimes also can produce severe complication, should actively prevent and treat.Primary disease all can be fallen ill the whole year, but occurred frequently with winter-spring season, can propagate by containing the virulent spittle or contaminated hands and apparatus, and mostly be and distribute, but can be popular when abrupt change of climate.

Summary of the invention

The purpose of this invention is to provide a kind of medicament for the treatment of acute upper respiratory tract infection.

in order to realize purpose of the present invention, the invention provides a kind of medicament for the treatment of acute upper respiratory tract infection, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Radix Angelicae Dahuricae 15-25 part, Flos Inulae 5-15 part, Semen Vaccariae 10-30 part, Herba Aristolochiae 1-15 part, Radix Saposhnikoviae 10-20 part, Herba Artemisiae Scopariae 15-30 part, Radix Bupleuri 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Radix Phytolaccae 10-20 part, Flos Buddlejae 15-20 part, Herba Sarcandrae 15-30 part, Radix Ranunculi Ternati 10-20 part, Folium Sennae 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Rhizoma Cyperi 15-25 part, Calyx Seu Fructus Physalis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Semen Euryales 1-20 part and Flos Rhododendri Mollis 10-25 part.

preferably, the medicament for the treatment of acute upper respiratory tract infection of the present invention is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of the Radixs Angelicae Dahuricae, 13 parts of Flos Inulaes, 28 parts of Semen Vaccariae, 11 parts of Herba Aristolochiaes, 17 parts of Radix Saposhnikoviaes, 24 parts of Herba Artemisiae Scopariaes, 27 parts of Radix Bupleuri, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Radix Phytolaccaes, 19 parts of Flos Buddlejaes, 15 parts of Herba Sarcandraes, 14 parts of Radix Ranunculi Ternatis, 21 parts of Folium Sennae, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Rhizoma Cyperis, 14 parts of Calyx Seu Fructus Physaliss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts of 16 parts of Semen Euryaless and Flos Rhododendri Mollis.

More preferably, described medicament can be tablet, dispersible tablet, capsule or decoction.

Whole compositions of the medicament for the treatment of acute upper respiratory tract infection of the present invention are all natural materials, and safety is better, and curative effect is clear and definite, are suitable for large-scale promotion clinically.

The specific embodiment

Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for explanation the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, otherwise the percent in the present invention is percetage by weight.

Embodiment decoction of the present invention

take Radix Scrophulariae 7 grams, Rhizoma Zingiberis 13 grams, Fructus Corni 22 grams, Radix Platycodonis 15 grams, the Radix Angelicae Dahuricae 21 grams, Flos Inulae 13 grams, Semen Vaccariae 28 grams, Herba Aristolochiae 11 grams, Radix Saposhnikoviae 17 grams, Herba Artemisiae Scopariae 24 grams, Radix Bupleuri 27 grams, Radix Morindae Officinalis 18 grams, Herba Chelidonii 17 grams, Rhizoma Imperatae 23 grams, Fructus Xanthii 21 grams, Fructus Phyllanthi 16 grams, Folium Et Cacumen Murrayae 16 grams, Radix Phytolaccae 17 grams, Flos Buddlejae 19 grams, Herba Sarcandrae 15 grams, Radix Ranunculi Ternati 14 grams, Folium Sennae 21 grams, Radix seu Herba Gei aleppici 11 grams, Radix Rhapontici 13 grams, Folium Rhododendri Daurici 23 grams, Rhizoma Cyperi 24 grams, Calyx Seu Fructus Physalis 14 grams, Cortex Mori 25 grams, Herba Eupatorii Lindleyani 26 grams, Semen Euryales 16 grams and Flos Rhododendri Mollis 24 grams, add 2000 milliliters of entry, in being housed, heated 4 hours under 80 ℃ by the flask of condensing tube, filter.Filtrate is concentrated into 600 milliliters, namely gets decoction of the present invention.

Experimental example

Select emergency treatment acute upper respiratory tract infection patient 60 examples, male 30 examples wherein, female's 30 examples, minimal ages 18 years old, maximum 56 years old age.Inclusive criteria: 1. meet relevant " the high heat of the acute upper respiratory tract infection " diagnostic criteria (Wu Shaozhen in " diagnosis of common disease and curative effect determinate standard ", Wu Min. the diagnosis of common disease and curative effect determinate standard [M]. Beijing: China Traditional Chinese Medicine Publishing House, 1999:140-142.): onset is anxious, the inducement such as suffer from cold, overworked or with the Patients With Respiratory Tract Infection contact history; Clinical symptoms can show as cough, expectorant is the amount doesn't matter, pharyngalgia, general pain, nasal obstruction, watery nasal discharge, hoarseness; Axillaty temperature is more than 38.5 ℃; The two lung auscultation respiratory murmurs of having a medical check-up are normal or increase thick or audible and dried, moist rales.Chest X-ray shows normal or enhanced lung markings.2. fall ill in 72h.3. the age is more than 14 years old or below 70 years old.4. without the medication contraindication.5. be not associated with cardiovascular and cerebrovascular disease and serious hepatorenal disease.6. patient's informed consent.

Therapeutic Method:

Use the decoction for preparing in embodiment to treat, every day 2 times, each oral 50 milliliters.Treatment was 1 course for the treatment of in 3 days continuously.

The clinical recovery criterion:

Meet " diagnosis of common disease and curative effect determinate standard " (Wu Shaozhen, Wu Min. the diagnosis of common disease and curative effect determinate standard [M]. Beijing: China Traditional Chinese Medicine Publishing House, 1999:140-142.), that is: 1. produce effects: after medication, in 24h, the cardinal symptoms such as General Symptoms and local pyrexia, cough, pharyngalgia disappear or basic the disappearance; 2. effective: in medication 24-48h, the cardinal symptoms such as General Symptoms and local pyrexia, cough, pharyngalgia disappear or basic the disappearance; 3. invalid: do not meet above standard person all be considered as invalid.

Result:

After treating 1 course for the treatment of, all patients all meet the standard of produce effects.

Claims

1. medicament for the treatment of acute upper respiratory tract infection, it is characterized in that, it is to be made by the material of following weight proportioning: Radix Scrophulariae 5-10 part, Rhizoma Zingiberis 10-20 part, Fructus Corni 20-30 part, Radix Platycodonis 10-20 part, Radix Angelicae Dahuricae 15-25 part, Flos Inulae 5-15 part, Semen Vaccariae 10-30 part, Herba Aristolochiae 1-15 part, Radix Saposhnikoviae 10-20 part, Herba Artemisiae Scopariae 15-30 part, Radix Bupleuri 20-30 part, Radix Morindae Officinalis 1-20 part, Herba Chelidonii 1-20 part, Rhizoma Imperatae 10-25 part, Fructus Xanthii 10-30 part, Fructus Phyllanthi 1-20 part, Folium Et Cacumen Murrayae 15-20 part, Radix Phytolaccae 10-20 part, Flos Buddlejae 15-20 part, Herba Sarcandrae 15-30 part, Radix Ranunculi Ternati 10-20 part, Folium Sennae 10-25 part, Radix seu Herba Gei aleppici 5-15 part, Radix Rhapontici 1-20 part, Folium Rhododendri Daurici 15-25 part, Rhizoma Cyperi 15-25 part, Calyx Seu Fructus Physalis 10-20 part, Cortex Mori 15-25 part, Herba Eupatorii Lindleyani 20-30 part, Semen Euryales 1-20 part and Flos Rhododendri Mollis 10-25 part.

2. the medicament for the treatment of acute upper respiratory tract infection according to claim 1, it is characterized in that, it is to be made by the material of following weight proportioning: 7 parts of Radix Scrophulariaes, 13 parts of Rhizoma Zingiberiss, 22 parts of Fructus Corni, 15 parts of Radix Platycodoniss, 21 parts of the Radixs Angelicae Dahuricae, 13 parts of Flos Inulaes, 28 parts of Semen Vaccariae, 11 parts of Herba Aristolochiaes, 17 parts of Radix Saposhnikoviaes, 24 parts of Herba Artemisiae Scopariaes, 27 parts of Radix Bupleuri, 18 parts of Radix Morindae Officinaliss, 17 parts of Herba Chelidoniis, 23 parts of Rhizoma Imperataes, 21 parts of Fructus Xanthii, 16 parts of Fructus Phyllanthis, 16 parts of Folium Et Cacumen Murrayae, 17 parts of Radix Phytolaccaes, 19 parts of Flos Buddlejaes, 15 parts of Herba Sarcandraes, 14 parts of Radix Ranunculi Ternatis, 21 parts of Folium Sennae, 11 parts of Radix seu Herba Gei aleppici, 13 parts of Radix Rhapontici, 23 parts of Folium Rhododendri Daurici, 24 parts of Rhizoma Cyperis, 14 parts of Calyx Seu Fructus Physaliss, 25 parts of Cortex Mori, 26 parts of Herba Eupatorii Lindleyanis, 24 parts of 16 parts of Semen Euryaless and Flos Rhododendri Mollis.

3. the medicament for the treatment of acute upper respiratory tract infection according to claim 1, is characterized in that, described medicament can be tablet, dispersible tablet, capsule or decoction.